Improving diagnosis and treatment for type 2 inflammatory skin diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to enhance the diagnosis and treatment of type 2 inflammatory skin diseases, such as atopic dermatitis and prurigo nodularis, by establishing a standardized center for these conditions. The initiative will systematically assess the current treatment practices and evaluate the efficacy and safety of various treatment methods. By gathering and analyzing data from patients diagnosed with these skin diseases, the project seeks to improve overall treatment outcomes and patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details);
2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis).

Exclusion Criteria:

1. patients who fail to provide informed consent form;
2. patients who cannot complete the questionnaire independently or under the guidance of investigators

Where it's running

• Peking University First Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yang Wang, Doctor
• Email: yangwang_dr@bjmu.edu.cn
• Phone: 008613811232795

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new hydrogel for treating mild to moderate eczema

  This study is testing a new hydrogel called zabalafin to see if it helps people with mild to moderate eczema feel better compared to a placebo.

  Recruiting at 12 sites Phase 2 Alphyn Biologics · Brookvale, New South Wales and 11 other locations · NCT06855745

• Herbal ointment for treating atopic dermatitis

  This study is testing a herbal ointment made from a plant to see if it can help people with atopic dermatitis feel better.

  Recruiting Phase 2/3 En Chu Kong Hospital · New Taipei City · NCT06850311

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Skin structure in atopic dermatitis patients treated with nemolizumab assessed by reflectance confocal microscopy

  This study tests whether nemolizumab changes skin structure in adults with moderate-to-severe atopic dermatitis using a noninvasive imaging method.

  Recruiting Hôpitaux Drôme Nord · Romans-sur-Isère, Drôme · NCT07730788

• Global Health Look at Atopic Dermatitis

  A worldwide, multicenter study tests how people with atopic dermatitis access care and treat it, using data from routine medical records.

  Recruiting University of Zurich · Zurich · NCT07659756

• cfDNA–STING pathway as a marker in atopic dermatitis

  This study will test whether small fragments of DNA in the blood and STING pathway activity in skin match disease severity in adults with atopic dermatitis.

  Recruiting Zhongda Hospital · Nanjing, Jiangsu · NCT07573735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.